This investigation highlighted CCNA2, TRIP13, CDK1, CDC20 and PRC1 as viable targets for our structure-based drug discovery campaign, as they all had a crystallised structure available in the Protein Data Bank, strong evidence of a role in ovarian cancer and known inhibitors (Table 2). This evidence concerns the gene CDK1 and ovarian cancer.